Immunotherapy involves harnessing the patient’s own immune system to fight cancer. One class of immunotherapy involves the engineering of patient T cells to express a Chimeric Antigen Receptor (CAR) that directs T cells to seek out and kill cancer cells. CAR-T products have been successful in treating some blood cancers, but their application in the setting of solid tumours has proven to be more problematic, due to issues of tumour diversity and poor T cell infiltration. Dendritic cells (DCs) represent an attractive alternative cellular immunotherapy due to their ability to take up tumour-associated antigens and promote polyclonal T-cell expansion, functional polarisation and tumour killing. Although monocyte-derived DCs have been extensively trialled as tumour “vaccines” with limited success, recent evidence has shown that it is type 1 conventional DCs (DC1s) that best promote anti-tumour immunity. In this research program, we aim to develop a novel cell therapy platform whereby DC1s are engineered with CAR constructs (CAR-DC1s) to precisely target solid tumours. More specifically, CAR-DC1s better recognise tumour cells and initiate potent and persistent anti-tumour responses. We identified a proprietary lead CAR-DC1 construct which displayed superior antigen presentation capacity and evoked proinflammatory anti-tumour T cells responses. Thus we propose a potentially a first-in-class cell therapy platform to address the large unmet need of treating cancer patients unresponsive to current treatments, especially those with intractable solid cancers.